Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. - Wikidata - awgldk - TriplyDB

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

http://www.wikidata.org/entity/Q33288091

about

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Patient assessment for cardiac resynchronization therapy: Past, present and future of imaging techniques.Optimized treatment and heart rate reduction in chronic heart failure.β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction.GENETIC CAUSES OF DILATED CARDIOMYOPATHY.The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010 Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation load.Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.Primary prevention of heart failure.Diagnosis and treatment of asymptomatic left ventricular systolic dysfunction after myocardial infarction.Beta-blocker use for the stages of heart failure.Chronic heart failure: we are fighting the battle, but are we winning the war?Potential novel pharmacological therapies for myocardial remodelling.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Myocardial reverse remodeling.Narrative review: the management of acute decompensated heart failure.Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy.Adrenoreceptors and nitric oxide in the cardiovascular system.Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.Anthracycline-Induced Cardiomyopathy in Adults.A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms.Using genetic testing to guide therapeutic decisions in cardiomyopathy.Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure.Identification of high-risk chronic heart failure patients in clinical practice: role of changes in left ventricular function.Early regression of left ventricular hypertrophy after treatment with esmolol in an experimental rat model of primary hypertension.Beta-blockers: acting in the brain but healing the heart.Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension.

P2860

Q24234511-14D3247D-FD33-4300-9AB5-0D486659B439 Q24241097-633601EB-B981-4361-AD56-6C8F78A8F6CD Q26853063-961F8FFC-6452-44B3-865F-E5D1A76D9460 Q30248340-663FE09E-E2DD-4A44-8B3D-5C6444306F6E Q30477756-3A06E602-51A9-4FD9-9BE0-FAD0B632BED7 Q33843442-83862C93-221D-4E4A-9CD2-F103E4EE3B55 Q34178045-F8E366E0-F723-4EB7-BFB4-F97A14F294AA Q34881335-41A5B4E8-6FDF-475B-ABCE-B53C8DAA8580 Q35335608-6B391370-4AB1-4EE5-A9F8-DD4538F21AAD Q35555534-10F7D190-78AD-48C1-9F42-438FA27821E0 Q35690546-FB78F632-3D02-4550-928F-99BA6D52A0EC Q36069669-93BCD006-83CE-49DF-BAFB-8C9851860F8D Q36094884-B1390F2E-BA60-497F-97D4-78A0F8343730 Q36200030-7638F80E-233F-484C-8353-6E62E3CBF50F Q36723119-4B1ABA6B-F7E4-4D89-8C63-F564E05C2491 Q37285564-33F66E3A-C1D1-46C6-AE27-2CF83A6FB9B2 Q37288386-75D9BB12-88B8-4884-B739-BE30A384E18E Q37329709-C2818A66-1BF3-411B-A03C-5EF80938F66D Q37395298-9A181C9A-1DF4-4605-A5CE-8E88D9629D3F Q37812403-C78F017A-EBFF-42AE-8223-93A3E204B7C3 Q37880500-55B3AD4E-5651-4585-846F-336CF5C2C741 Q37910906-E0CEC35C-07FD-41DF-953A-12592CF2015F Q38162217-38F9B6D7-E76F-4377-9CAF-136CBB30F9FD Q38170307-E9E5E86E-B83B-47A8-ACAA-6C04FCB0CDFA Q38248810-4A463274-CCE3-4430-AF0A-716CD2789ECA Q38542462-66F3FE86-B46E-4EE7-9525-2716E1090675 Q38542681-4DD832F1-3E3B-44F6-8AB4-85DF97519CE3 Q39398133-0C368BF2-E799-49D9-90C3-F8FD6E8EC25E Q41899817-C6033B84-D555-4A72-9706-2D31A7966949 Q43190662-89CF1B57-BF0F-4F8F-909E-3393B931A90A Q43907909-E32E6337-F114-4253-9F32-D648B8A0CFC9 Q44612465-4EBFC8C6-FC7F-4A1A-9FA1-573A0B5D755E Q49025875-77F7A89D-3A41-4E1F-AEB1-2099975F2F43 Q51513633-DFF543E6-2635-4775-8889-715D1D228260

P2860

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

http://www.wikidata.org/entity/Q33288091

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@ast

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@en

Metoprolol reverses left ventr ...... ular Remodeling with Toprol-XL

@nl

type

label

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@ast

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@en

Metoprolol reverses left ventr ...... ular Remodeling with Toprol-XL

@nl

prefLabel

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@ast

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@en

Metoprolol reverses left ventr ...... ular Remodeling with Toprol-XL

@nl

P1433

Q33288091-C182AE48-209E-4F9D-A8C4-552429ABBAB6

P1476

Q33288091-9EF56CC0-5B83-478F-BDC1-0A09A1951277

P2093

Q33288091-000D6640-BAE9-4B74-9C55-5E67D25EEC73

Q33288091-135F24CC-08C2-4FFE-A52A-497450B6D765

Q33288091-216BC21E-B736-4094-94F6-3A245EB2AD6B

Q33288091-3E9FEF89-DBCC-4291-8494-2BB2878B3F3B

Q33288091-59B39A7D-6FE2-4261-B4D7-649F1D053833

Q33288091-7024F86B-D515-4A95-AB0C-EDC9C3E82C98

Q33288091-EBF4EB1B-2033-4585-91CE-5EC980F1EF8A

Q33288091-EEFE9FE7-959D-4385-A3AE-6756757BE8DE

Q33288091-F92FED29-8431-4FAB-9FDF-73C0D6CBAE7E

Q33288091-FE3879DA-BA0F-4B4D-97AF-F368A7F9BAEB

P304

Q33288091-1E87E1DC-4D2C-4E7C-ABA6-AEA8942F883B

P31

Q33288091-874FD6FA-8C62-4953-BFC8-D601287D2550

P356

Q33288091-C639171B-9B0A-49FB-AA06-030CEE4B7647

P407

Q33288091-89F00656-7432-4F8F-8E73-27338639BBF3

P433

Q33288091-D032B8BA-B1A1-4A48-854F-1C2E3F19B1DF

P478

Q33288091-BA73914E-798A-482D-AC33-6CA5A201B7CF

P50

Q33288091-F63E675A-18B7-4879-B38A-EF9105226330

P577

Q33288091-C8302C6A-BFE2-4C48-9986-340E8F0F4085

P5875

Q33288091-2E505F65-3484-4F1F-B43D-087C80F059F4

P698

Q33288091-DC79A454-BD42-43A1-BC3D-5257E569EB9A

P921

Q33288091-8E086741-AC01-4966-BDD5-C57BCCC72C86

Q33288091-E5948404-CE41-4175-BA43-96A142CAF830

P356

CIRCULATIONAHA.106.666016

P1433

P1476

Metoprolol reverses left ventr ...... with Toprol-XL (REVERT) trial.

@en

P2093

Barry Greenberg

http://www.w3.org/2001/XMLSchema#string

Jalal K Ghali

http://www.w3.org/2001/XMLSchema#string

Jennifer E Sugg

http://www.w3.org/2001/XMLSchema#string

Kirkwood F Adams

http://www.w3.org/2001/XMLSchema#string

Marrick L Kukin

http://www.w3.org/2001/XMLSchema#string

Michael I Klibaner

http://www.w3.org/2001/XMLSchema#string

REVERT Study Group

http://www.w3.org/2001/XMLSchema#string

Stephen S Gottlieb

http://www.w3.org/2001/XMLSchema#string

Theodore J Kolias

http://www.w3.org/2001/XMLSchema#string

William F Armstrong

http://www.w3.org/2001/XMLSchema#string

P304

49-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.106.666016

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Wilson S Colucci

P577

2007-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6260029

http://www.w3.org/2001/XMLSchema#string

P698

17576868

http://www.w3.org/2001/XMLSchema#string

P921